Incyte
Update in progressINCY (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. It markets Jakafi for myelofibrosis, polycythemia vera, and steroid-refractory GVHD; Iclusig for CML and Ph+ ALL; Pemazyre for FGFR-driven biliary tract cancers; Zynyz for Merkel cell carcinoma; MONJUVI for DLBCL and FL; NIKTIMVO for chronic GVHD. It has collaborations with Novartis, Lilly, and Syndax. Headquarters: Wilmington, Delaware.
Company score
- Sentiment
- 1.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.13
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 1.17
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.33
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.79
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. William J. Meury
- Founded1991
- Employees2,844
- Websitewww.incyte.com
Identifiers
- ISINUS45337C1027
- FIGIBBG000BNPSQ9
- LEI549300Z4WN6JVZ3T4680
- CUSIP45337C102
- CIK0000879169